Abstract
The nonpoliovirus enteroviruses commonly infect newborns, with consequences ranging from asymptomatic infection and benign illness, to severe, life-threatening disease. Frequently occurring symptoms include fever, irritability, lethargy, anorexia, and rash. Although most illnesses are mild, severe disease develops in a subset of newborns infected in the first 2 weeks of life. Severe disease may consist of sepsis, meningoencephalitis, myocarditis, pneumonia, hepatitis, and/or coagulopathy. Substantial mortality rates have been reported, and long-term sequelae may occur among survivors. Risk factors and clinical features associated with severe disease include absence of neutralizing antibody to the infecting serotype, maternal illness prior to or at delivery, prematurity, illness onset within the first few days of life, multiorgan disease, severe hepatitis, positive serum viral culture, and specific infecting serotype (e.g. group B coxsackieviruses and echovirus 11).
Whereas the mainstay of diagnosis has traditionally been viral isolation in tissue culture, the polymerase chain reaction has been demonstrated to be more sensitive than culture, highly specific, and rapid. Immunoglobulin has been used as a therapeutic agent for neonates with enterovirus disease; however, clinical efficacy has not been proven.
Specific antiviral therapy for enteroviruses is in development. Pleconaril is an investigational agent that inhibits viral attachment to host cell receptors and uncoating of viral nucleic acid. It has broad and potent anti-enterovirus activity, excellent oral bioavailability, and is well tolerated. Some clinical trials have demonstrated benefit in children and adults with enterovirus meningitis, and in adults with upper respiratory tract infections caused by picornaviruses (rhinoviruses or enteroviruses). Data summarizing compassionate use for severe enterovirus diseases (including neonatal sepsis) also suggest possible benefit. Limited pharmacokinetic data are available in infants and neonates. A multicenter, placebo-controlled, randomized trial of pleconaril in neonates with severe hepatitis, coagulopathy, and/or myocarditis is currently being conducted.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Enteroviruses are small, single-stranded RNA-containing viruses within the Picornaviridae family. They have traditionally been divided into subgroups, including polioviruses, coxsackie A viruses, coxsackie B viruses, and echoviruses, based on replication properties in tissue culture and animal models, with newer enteroviruses designated by number rather than by subgroup designation.[1,2] More recently, the enteroviruses have been reclassified into five species (polioviruses and enteroviruses A–D), based on nucleotide and amino acid sequences.[3] The more than 60 serotypes within the genus enterovirus are distinguished by antigenic differences.[2]
Enteroviruses are common causes of human infection. Polioviruses cause paralytic poliomyelitis, which continues to be prevalent in some areas of the developing world. The nonpoliovirus enteroviruses, the focus of this article, cause a large number and a broad spectrum of diseases. These include mild conditions such as nonspecific febrile illnesses, herpangina, uncomplicated hand-foot-and-mouth disease, and respiratory tract infections, as well as potentially severe illnesses such as meningitis, encephalitis, paralytic disease, myocarditis, chronic or disseminated infection in immunocompromised hosts (e.g. patients with hypogammaglobulinemia or bone marrow transplant recipients), and neonatal sepsis. The incidence and severity of enterovirus infections are, in general, inversely related to age. In temperate climates, enterovirus infections have a distinct seasonality, with infections occurring predominantly in the summer and fall months.[1,2,4]
The objectives of this article are to describe the clinical and epidemiologic features of neonatal enterovirus infections, to discuss current diagnostic approaches, and to present the available information regarding potential therapies.
1. Clinical Overview
Infection by nonpoliovirus enteroviruses in the newborn period can be asymptomatic, manifest as a benign illness, or produce severe, life-threatening disease.[5,6] The majority of these infections are asymptomatic.[7] Most neonates who develop clinical illness were born at term following uncomplicated pregnancies and deliveries, and have had normal neonatal courses before onset of enterovirus disease.[5,8,9] History frequently (59–68%) includes a maternal viral illness preceding or immediately following delivery, with symptoms such as fever, respiratory findings, and/or abdominal pain. The latter may suggest a diagnosis of chorioamnionitis or abruptio placentae. Viral symptoms are also commonly present in other family members.[1,5,6,8–10] Newborns can present with symptoms throughout the neonatal period; some manifest illness as early as day 1 of life. Symptoms and signs include fever or hypothermia, irritability, lethargy, anorexia, decreased perfusion, jaundice, abdominal distension, emesis and, occasionally, diarrhea.[5,8,9] Although diarrhea may occasionally be bloody or severe,[9,11] in most reports it is not a dominant finding. Respiratory findings may include tachypnea, cough, grunting, retracting, wheezing, rhinorrhea, or apnea.[5,8,9] Rashes, frequently macular or maculopapular, and occasionally papulovesicular, nodular, or bullous, are often present and may suggest a viral diagnosis.[12,13]
Most affected neonates have mild illness without sequelae. Fever generally resolves in an average of 3 days and other symptoms regress in approximately 7 days.[5,8,9] Severe illness develops in a minority of infected newborns, particularly in the first 2 weeks of life.[14] A biphasic pattern, in which mild disease is followed by a short period of recovery followed by more severe illness, may occasionally occur. Severe disease consists of any combination of sepsis, meningoencephalitis, myocarditis, pneumonia, hepatitis, and coagulopathy. Encephalitis is suggested by extreme lethargy that may progress to depressed consciousness. Seizures or focal neurologic abnormalities may develop, and a bulging fontanelle or nuchal rigidity may occasionally be evident.[8,15–17] Myocarditis manifests as cardiomegaly, congestive heart failure, arrhythmias, and/or myocardial infarction; pericarditis may also occur.[18–20] Myocarditis may present as a biphasic illness.[21] Pneumonia can be rapidly progressive and severe.[22–24] Hepatitis is characterized by jaundice, hepatomegaly, elevated transaminases, and hyperbilirubinemia, and is frequently associated with thrombocytopenia and coagulopathy. Acute hepatic necrosis and endothelial injury, liver failure, bleeding complications, and renal failure may ensue.[8,10,25,26] Intracranial hemorrhage can be a life-threatening complication.[25,27] Renal and adrenal hemorrhagic necrosis may also develop.[28] Other more unusual complications of neonatal enterovirus infections include necrotizing enterocolitis, myositis, pancytopenia, hemophagocytic syndrome, and hyponatremia with inappropriate antidiuretic hormone secretion.[8,9,11,29,30]
Retrospective reports and literature reviews suggest mortality rates of neonatal enterovirus infections ranging between 0% and 83%.[5,6,8,9] Myocarditis and hepatitis with coagulopathy are associated with the greatest mortality.[6,8,25] Thirty-one percent of neonates with hepatitis or coagulopathy died in one retrospective series; mortality was especially high when hepatitis and myocarditis occurred together.[25] Fortunately, the prognosis for survivors is generally favorable, even after severe disease. Most neonates who survive myocarditis do not have long-term cardiac sequelae, although residual myocardial dysfunction, chronic calcific myocarditis with chronic heart failure and dysrhythmias, and ventricular aneurysm have all been reported.[18,19,31,32] Hepatic dysfunction following hepatitis may persist into infancy and hepatic calcification may become evident; however, the majority of survivors eventually have return of normal liver function and maintain satisfactory growth.[25,33] The prognosis for neonates with central nervous system involvement is more difficult to predict. Some studies described long-term sequelae, for example delayed speech and language development, intellectual deficits, motor abnormalities (spasticity, hypotonicity, and weakness), seizure disorders, ocular defects, and microcephaly, while others did not identify long-term neurologic deficits.[8,16,34–39] Severe encephalitis may be associated with necrosis and subsequent neurologic compromise, including reduced intelligence, motor abnormalities, or hydrocephalus.[17,34,35]
2. Epidemiology
Enterovirus infections occur frequently during pregnancy. A 10-year seroepidemiologic survey revealed that 42% of 1794 pregnant women were infected with enteroviruses.[40] Another study found that 25% of pregnant women had serologic evidence of an enterovirus infection during the 3-month period surrounding delivery during peak enterovirus season. Additionally, 3–4% of pregnant women shed enteroviruses from the throat or rectum, near delivery, during enterovirus season, frequently with minimal or no symptoms.[41]
Nonpoliovirus enterovirus infections of neonates are also common. Thirteen percent of infants <1 month of age were infected by an enterovirus during the summer and fall months (July–October) in one study; 21% of the infected newborns were symptomatic. Enterovirus infections accounted for 65% of hospital admissions of infants <3 months of age with suspected sepsis in the summer and fall in the same community.[7,42] In another report, asymptomatic or symptomatic neonatal enterovirus infections were detected by culture in 5% of infants, and by serology in 7% of infants during enterovirus season.[41] In a study of neonates evaluated for possible sepsis during a 13-month period, 4% were found to have an enterovirus infection.[43] Enteroviruses were the most frequently identified etiology of meningitis, occurring between days 8 and 29 of life at one institution, and accounting for at least one-third of cases.[44] Application of the sensitive polymerase chain reaction (PCR) test has added to our understanding of the frequency of enterovirus infections in young infants. In one community, during a 1-year period enteroviruses were detected by PCR in 26% of hospitalized, febrile infants ≤90 days of age, peaking at 50% during the summer and fall (June–November).[45] Similarly, in a multicenter study, enteroviruses were responsible for 59% and 48% of hospital admissions in infants ≤90 days of age and ≤30 days of age, respectively, in the summer and fall (July–October), as determined by viral culture and PCR.[46] Overall, estimates suggest that neonatal enterovirus disease occurs at an incidence greater than or equal to that of Streptococcus agalactiae, herpes simplex virus, and cytomegalovirus.[6–8]
Most enterovirus-infected neonates are presumed to acquire infection either intrapartum by exposure to maternal blood or genital secretions, or after delivery by exposure to oropharyngeal secretions or stool of mothers or other contacts.[6,9,47] Enteroviruses have been grown from the throat, rectum, and cervical swabs from pregnant women and from mothers of infected, ill neonates.[41,48–51] High rates of viral illness in the peripartum period among siblings and fathers of enterovirus-infected newborns also suggest the possibility of transmission from these family members.[5] A modest number of cases of neonatal enterovirus disease with onset in the first few hours after birth have been reported, suggesting that some neonatal enterovirus infections are acquired in utero. Culture of enteroviruses from amniotic fluid and umbilical cord blood, detection of enterovirus antigens in myocardia hours after delivery, culture of enteroviruses from neonatal organs a few hours after birth, and detection of neutralizing immunoglobulin (Ig)M antibody in serum on day 1 of life all further support this possibility.[23,48,52–55] Identification of enteroviruses in placentas suggests that some in utero infections may occur via a transplacental route;[56–59] shedding of enteroviruses from the stool and cervix of pregnant women, and growth of enteroviruses from amniotic fluid, also indicate the potential for ascending infection.[8,41,49–51,53,57,60] Based on the presence of viremia or symptoms in the first 1–2 days after delivery, it has been estimated that approximately 22% of fatal neonatal coxsackie B virus infections and 11% of neonatal echovirus infections were acquired in utero.[6,8,15,22]
Epidemic spread and sporadic transmission of enteroviruses in hospital nurseries have been reported.[6,8,11,48,55,61–66] Several outbreaks could be traced to vertically infected neonates, with subsequent spread by nursery staff, whereas adults were considered to have introduced enteroviruses into nurseries in other outbreaks.[6] Risk factors for acquiring enterovirus infection in the nursery include prematurity, low birth weight, intensive care, and nasopharyngeal or oropharyngeal instrumentation.[58,59,62] Nosocomially acquired infections tend to be associated with milder disease and lower mortality than vertically acquired infections.[6]
One of the major risk factors for the development of clinically significant enterovirus disease is the absence, or low titer, of maternally derived neutralizing antibody to the infecting enterovirus serotype.[10,63,64,67] Other risk factors and clinical features associated with severe neonatal disease include maternal illness prior to or at delivery, prematurity, onset of illness within the first few days of life, multiorgan involvement, severe hepatitis, positive serum viral culture, and certain infecting serotypes (e.g. group B coxsackieviruses and echovirus 11).[5,6,8–10,67–69]
3. Laboratory Evaluation and Diagnosis
The peripheral white blood cell count may be normal or elevated with enterovirus infection; elevated counts have been observed in 10–20% of infected neonates. The band count may also be increased.[5,9] Cerebrospinal fluid pleocytosis suggestive of viral meningitis may be present (usually <500 white blood cells/mm3) in 35–50% and, occasionally, may mimic bacterial meningitis, with up to several thousand white blood cells/mm3. A neutrophil predominance is frequently present, and increased protein or decreased glucose levels may sometimes occur.[5,9] Conversely, cerebrospinal fluid may be positive by culture or PCR despite normal cell counts and chemistries.[5,8,9] CNS imaging is advisable in the presence of profound lethargy, focal neurologic findings, or neurologic deterioration in the setting of significant thrombocytopenia or coagulopathy. If a newborn is systemically ill, or if findings suggestive of hepatic involvement (e.g. hepatomegaly or jaundice) or bleeding are present, transaminases and bilirubin should be assessed. If hepatic disease is severe, ammonia levels may need to be monitored, especially if profound lethargy is present. In an infant with hepatitis or bleeding, or in any newborn that is systemically ill, the platelet count and coagulation profile should be monitored. A chest radiograph is indicated if respiratory or cardiac symptoms are present. Infiltrates suggest pneumonia or heart failure; cardiac enlargement suggests myocarditis or pericarditis. If cardiac disease is suspected, echocardiography can define myocardial function, cardiac size, and presence of a pericardial effusion. An electrocardiogram may be useful to evaluate for dysrhythmias, decreased voltage (reduced amplitude), and/or evidence of myocardial infarction.[8,19,20] Scintigraphic imaging has also been used to detect neonatal myocarditis.[70]
The mainstay of specific diagnosis for enterovirus infections has traditionally been viral isolation in cell culture. A variety of cell lines support enteroviruses, for example monkey kidney cells and human fibroblast, epithelial, and rhabdomyosarcoma cell lines. No single line is optimal for all enteroviruses; therefore, diagnostic laboratories typically use a combination of cell types, such as a monkey kidney line and a fibroblast line.[1] Viral culture specimens with the highest yield in neonatal enterovirus infections are rectum or stool (91–93% positive), cerebrospinal fluid (62–83% positive), and nasopharynx or throat (52–67% positive). Cultures of serum and urine have lower yields (24–47%); however, serum specimens may grow virus more rapidly than other body fluids/sites.[5,9,71] Serum cultures are more likely to be positive with echoviruses, low serum neutralizing antibody titer, and onset of illness within the first 5 days of life.[69,71]
Tissue culture has some significant limitations. It requires expertise and is relatively expensive. Not all enterovirus serotypes grow in culture; coxsackie A viruses, in particular, grow poorly in culture. Sensitivity of culture is further limited by neutralizing antibody in diagnostic specimens, inadequate specimen collection or handling, and insensitivity of some cell lines for some serotypes. Additionally, growth in culture can be slow, ranging from 3 to >8 days. Methods more rapid than culture would be desirable to reduce unneeded diagnostic evaluations and treatments, and initiate potential therapies.[1] Antibody and antigen detection assays have been developed, but their sensitivity is suboptimal because an antigen shared by the majority of enteroviruses is lacking.[1] Enzyme immunoassay, counterimmunoelectrophoresis, and neutralization assays to detect IgG, IgM, and/or IgA antibodies to a variety of enteroviruses have been developed.[72,73] In general, their utility has been restricted by limited sensitivity; moreover, serologic assays are generally not useful for acute diagnosis unless the likely infecting serotype is known from epidemiologic circumstances and an IgM assay for that serotype is available. Antigen detection assays for stool samples and tissues have generally had suboptimal sensitivity.[74,75]
In contrast with antigen detection, application of the PCR to diagnosis of enterovirus infections has been very rewarding. Several sets of PCR primers and probes that detect the majority of enterovirus serotypes have been described. These are directed at highly conserved regions of the 5′ noncoding region of the enterovirus genome and are designed for reverse transcription combined with PCR (RT-PCR).[76] Enterovirus PCR assays detect most enterovirus serotypes implicated in neonatal disease. These tests are more sensitive than culture, and they approach 100% specificity in the absence of laboratory contamination.[76,77] Rapid formats that produce results in as little as 5 hours have been developed. PCR has been shown to be useful for diagnosis of pediatric enterovirus meningitis, nonspecific fever illnesses, and neonatal infections.[1] In these studies, PCR testing of cerebrospinal fluid, serum, and throat specimens from children with acute illnesses had sensitivities of >90% and high specificity; urine testing was somewhat less sensitive.[78,79] Rapid diagnosis afforded by PCR allows the possibility of significant cost savings and fewer interventions for infected infants.[80–82] In neonates, PCR of serum and urine specimens has been demonstrated to be more sensitive than culture of these specimens, with a yield approaching 90%. High sensitivity was maintained for the first several days of illness and provided more rapid diagnosis than culture.[5,9,83] Sensitivity also appears high with PCR assay of cerebrospinal fluid from neonates,[84] and PCR has been used to detect enterovirus in neonatal tissue.[85] PCR and nucleotide sequencing have assisted with the detection of viral spread in neonatal units and with infection control interventions.[86–91]
In general, positive cultures and PCR assays of mucosal sites such as the throat or rectum may reflect asymptomatic infection or presence of disease-causing virus. In contrast, positive culture and PCR tests of body fluids such as serum and cerebrospinal fluid more specifically suggest disease causation.[7,71] Nevertheless, a positive culture or PCR assay of a mucosal site in the first month of life (even without a positive assay of normally sterile body fluids), in the presence of an enterovirus-compatible illness, and in the absence of evidence of infection by another virus (e.g. herpes simplex virus, cytomegalovirus, or adenovirus) or a bacterial pathogen (e.g. group B streptococcus or Escherichia coli) or a noninfectious condition (e.g. metabolic disorder or structural cardiac disease) that can produce similar clinical findings, implicates an enterovirus as the likely etiologic agent. Viral culture or PCR of maternal rectal or cervical specimens may yield the same virus as that causing neonatal illness. Maternal serum may also have a significant titer of neutralizing antibody to the causative viral serotype;[9,15,69] however, diagnosis of a neonatal infection can usually be made directly from neonatal specimens.
The majority of neonatal enterovirus infections are caused by coxsackie B viruses and echoviruses; coxsackie A virus infections occur less frequently.[9] Coxsackieviruses B2–5 and echoviruses 6, 11, and 19 are frequent causes of severe neonatal disease,[6,8–10] although many other enterovirus serotypes have also been implicated. Associations between enterovirus subgroup and disease pattern have been observed, such as coxsackie B viruses with meningoencephalitis and myocarditis, and echoviruses with hepatitis and coagulopathy; however, significant overlap occurs.[6,8,10] For example, coxsackie B virus-associated hepatitis and coagulopathy has been increasingly reported in recent years.[92,93] In the absence of an epidemic, unique disease manifestations, or poliovirus circulation, identification of the enterovirus subgroup and serotype is generally unnecessary and does not affect diagnostic evaluation or therapy.
The differential diagnosis of neonatal enterovirus infections includes infections by other viruses (e.g. herpes simplex virus, cytomegalovirus, adenovirus, and rubella virus), and by bacteria (e.g. S. agalactiae and Gram-negative enterics). Additionally, noninfectious conditions such as metabolic disorders and congenital heart disease can mimic neonatal enterovirus disease.[1]
4. Therapy
Neonates with enterovirus disease generally require hospitalization for diagnostic evaluation and empiric treatment of possible bacterial or herpes simplex virus infection, because the symptoms of enterovirus infection are nonspecific. In addition, supportive care such as respiratory support, cardiovascular pharmacotherapy, and blood product administration may be required for severe disease.[5,9,63,94] Fulminant hepatic failure has been treated with selective gut decontamination,[95] peritoneovenous shunting,[96] and orthotopic liver transplantation.[26,94]
Immunoglobulin has been used as a therapeutic agent for neonates with enterovirus disease, for several reasons. Lack of type-specific serum antibody is a risk factor for symptomatic neonatal enterovirus infection. Ig products contain neutralizing antibodies to commonly circulating serotypes. Ig has been used successfully for patients with hypogammaglobulinemia with severe or chronic enterovirus infections.[67,69,97–99] Intramuscular or intravenous Ig has been administered to numerous neonates with severe enterovirus disease.[100–104] The combination of intravenous Ig and human leukocyte interferon has also been tried.[92] No clear conclusions can be made from these uncontrolled experiences. In the only randomized trial in neonates, administration of intravenous Ig (750 mg/kg) was associated with modest boosts of serum neutralizing antibody titers to viral isolates of patients, subtle clinical benefits, and faster cessation of viremia and viruria in patients who received a high titer (≥1 : 800) of neutralizing antibody to their own viral isolates;[69] however, the study population was too small for definitive conclusions. Infusion of maternal convalescent plasma has also been occasionally described and remains another potential, but unproven, treatment option.[105]
Specific antiviral therapy for enterovirus infections is currently in development. Agents that act at several key steps in the enterovirus life cycle, including attachment, uncoating, protease activity, and replication, are being evaluated. The investigational agent that has advanced furthest for the treatment of enteroviruses is pleconaril. This agent fits within a pocket beneath the floor of a canyon at the junctions of VP1 and VP3 on the viral capsid, and inhibits viral attachment to host cell receptors and uncoating of viral nucleic acid.[106,107] It has broad-spectrum and potent anti-enterovirus and anti-rhinovirus activity; it inhibits replication of more than 96% of the most commonly isolated enterovirus serotypes at achievable concentrations.[108] It is highly bioavailable (approaching 70%) after oral administration (the only route for which there is currently a preparation), achieving serum levels >0.1 μg/mL, the concentration required to inhibit >90% of commonly circulating enterovirus serotypes.[107,109] Preclinical data indicate that it concentrates 2- to 6-fold in the meninges, brain, and spinal cord. Experience to date suggests that pleconaril is well tolerated, with adverse events occurring at a frequency similar to, or slightly greater than, that observed with placebo.[106] Nausea, diarrhea, and headache are the most commonly reported adverse effects. Enterovirus isolates induced in vitro to become pleconaril-resistant were shown to have amino acid substitution in the pocket in which the drug binds within VP1 and, importantly, to be less stable and to have reduced replicative capacity and lethality in mice.[108]
Randomized, controlled clinical trials evaluating pleconaril in adults and children are summarized in table I.[110–115] These studies have generally utilized doses of 200–400mg three times daily in adults, and 2.5–5.0 mg/kg three times daily in children, usually for 5 to 7-day courses. Pediatric studies of pleconaril for enterovirus meningitis have had inconsistent results.[112,113] Results of pediatric studies of the treatment and prevention of upper respiratory tract infections are pending. An additional category for which pleconaril has been evaluated is severe enterovirus disease treated via a compassionate use mechanism. In a summary of this program between 1996 and 1998, 38 patients had received pleconaril for chronic enterovirus meningoencephalitis complicating agammaglobulinemia, neonatal enterovirus sepsis, enterovirus myocarditis, severe infection in bone marrow transplant recipients, acute enterovirus encephalitis, and poliomyelitis caused by wild-type poliovirus or live poliovirus vaccine. Clinical, laboratory, virologic, and radiologic responses were seen in 78%, 88%, 92%, and 60%, respectively, of patients evaluable for each category. Although these are uncontrolled, observational data, the response rates may be greater than what would be expected in untreated patients with similar diagnoses.[116]
Experience with pleconaril in infants and neonates is limited. In a small trial of pleconaril (5 mg/kg three times daily) in infants with enterovirus meningitis, 90% of peak and trough pleconaril levels exceeded the concentration required to inhibit 90% of clinical enterovirus isolates in vitro. A median 3.5-fold accumulation was observed during the 1-week treatment period, greater than the approximately 2-fold accumulation observed in adults.[117] In this study, pleconaril was well tolerated, although twice as many adverse events per patient were observed in the pleconaril group compared with the placebo group. Virologic and clinical efficacy were not demonstrable in this small trial. Data from a single-dose, phase I study in neonates suggest that potentially therapeutic concentrations of pleconaril are achievable in plasma with weight-adjusted doses similar to those used in older children; however, pharmacokinetics have not been established in critically ill newborns.[118] Uncontrolled, anecdotal reports of the use of pleconaril in neonates with severe enterovirus disease suggest that the medication is well tolerated in this population and may offer possible benefit.[119,120] A multicenter, placebo-controlled, randomized trial of pleconaril for neonatal enterovirus sepsis characterized by hepatitis, coagulopathy, and/or myocarditis is currently being conducted under the sponsorship of the National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group of the US National Institutes of Health. This study is examining pharmacokinetics, safety, and efficacy.[117]
Currently, pleconaril remains an experimental agent. Concerns regarding the induction of cytochrome P3A4 causing menstrual disorders in women taking oral contraceptives have held up licensure by the US FDA.[121]
5. Prevention
Vaccines for the nonpoliovirus enteroviruses are not available. The primary defense against transmission of enteroviruses is good hygiene, particularly hand washing to prevent fecal-oral and respiratory spread within families, preschool and school settings, and hospital nurseries. Infection control strategies such as cohorting have been effective in limiting nursery outbreaks. Ig or convalescent plasma has been administered intramuscularly or intravenously prophylactically in some nursery epidemics to prevent infection or ameliorate symptomatic disease. Simultaneous infection control interventions make it difficult to determine the efficacy of these approaches.[62,63,66,97,122–124]
Pregnant women near term should avoid contact with individuals who are ill with probable enterovirus infections. If a pregnant woman develops an illness likely to be caused by an enterovirus, it is advisable not to proceed with emergent delivery unless there is concern for fetal compromise or obstetric emergencies cannot be excluded. Rather, it may be advantageous to extend pregnancy, allowing the fetus time to passively acquire protective antibodies.[67] A strategy of prophylactically administering Ig to neonates born to mothers with enterovirus infections near delivery is a logical but untested approach.[31]
6. Conclusions
Enteroviruses can cause severe disease in newborns, including life-threatening manifestations such as hepatitis, coagulopathy, and myocarditis. Additionally, meningoencephalitis can be associated with long-term neurologic sequelae. The PCR is a significant diagnostic advance that provides accurate and rapid results. The current approach to therapy of neonates with severe enterovirus disease is supportive care, including respiratory and cardiovascular support and blood product administration. Ig has been used anecdotally and in small case series based on theoretical rationale and limited supportive clinical trial evidence; however, proof of efficacy is lacking. Specific antiviral therapy for enterovirus infections is needed, particularly for neonatal infections, and is in development. Pleconaril offers promise for neonatal enterovirus disease, based on demonstration of benefit in some studies in children and adults with enterovirus meningitis or picornavirus (rhinovirus and enterovirus)-associated upper respiratory disease and on positive compassionate use experience. Limited pharmacokinetic data are currently available in infants and neonates. The multicenter, placebo-controlled, randomized trial of pleconaril for neonatal enterovirus hepatitis, coagulopathy, and/or myocarditis currently being conducted will provide more definitive information regarding pharmacokinetics, safety, and efficacy of pleconaril in sick neonates.
References
Abzug MJ, Rotbart HA. Enterovirus infections of neonates and infants. Semin Pediatr Infect Dis 1999; 10: 169–76
Modlin JF. Introduction to picornaviridae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia (PA): Churchill Livingstone, 2000: 1888–95
King AMP, Brown F, Christian P, et al. Picornaviridae. In: Wickner RB, editor. Classification and nomenclature of viruses: seventh report of the international committee on taxonomy of viruses. New York (NY): Academic Press, 1999: 657–64
Modlin JF. Coxsackieviruses, echoviruses, and newer enteroviruses. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia (PA): Churchill Livingstone, 2000: 1904–19
Abzug MJ, Levin MJ, Rotbart HA. Profile of enterovirus disease in the first two weeks of life. Pediatr Infect Dis J 1993; 12: 820–4
Modlin JF. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev Infect Dis 1986; 8: 918–26
Jenista JA, Powell KR, Menegus MA. Epidemiology of neonatal enterovirus infection. J Pediatr 1984; 104: 685–90
Kaplan MH, Klein SW, McPhee J, et al. Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev Infect Dis 1983; 5: 1019–32
Lake AM, Lauer BA, Clark JC, et al. Enterovirus infections in neonates. J Pediatr 1976; 89: 787–91
Modlin JF. Fatal echovirus 11 disease in premature neonates. Pediatrics 1988; 66: 775–80
Birenbaum E, Handsher R, Kuint J, et al. Echovirus type 22 outbreak associated with gastro-intestinal disease in a neonatal intensive care unit. Am J Perinatol 1997; 14: 469–73
Theodoridou M, Kakourou T, Laina I, et al. Vesiculopapular rash as a single presentation in intrauterine coxsackie virus infection. Eur J Pediatr 2002; 16: 412–3
Sauerbrei A, Gluck B, Jung K, et al. Congenital skin lesions caused by intrauterine infections with coxsackievirus B3. Infection 2000 Sep; 28: 326–8
Verboon-Maciolek MA, Krediet TG, van Loon AM, et al. Epidemiological survey of neonatal non-polio enterovirus infection in The Netherlands. J Med Virol 2002; 66: 241–5
Kibrick S, Benirschke K. Severe generalized disease (encephalohepatomyocarditis) occurring in the newborn period and due to infection with coxsackie virus, group B: evidence of intrauterine infection with this agent. Pediatrics 1958; 22: 857–74
Rorabaugh ML, Berlin LE, Heldrich F, et al. Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications. Pediatrics 1993; 92: 206–11
Haddad J, Messer J, Gut JP, et al. Neonatal echovirus encephalitis with white matter necrosis. Neuropediatrics 1990; 21: 215–7
Goren A, Kaplan M, Glaser J, et al. Chronic neonatal coxsackie myocarditis. Arch Dis Child 1989; 64: 404–6
Hornung TS, Bernard EJ, Howman-Giles RB, et al. Myocardial infarction complicating neonatal enterovirus myocarditis. J Paediatr Child Health 1999; 35: 309–12
Shah SS, Hellenbrand WE, Gallagher PG. Atrial flutter complicating neonatal coxsackie B2 myocarditis. Pediatr Cardiol 1998; 19: 185–6
Rigourd V, Dommergues MA, Ayachi A, et al. Neonatal enterovirus myocarditis. Arch Pediatr 2002; 9: 495–8
Baker DA, Phillips CA. Maternal and neonatal infection with coxsackievirus. Obstet Gynecol 1980; 55: 12–15S
Boyd MT, Jordan SW, Davis LE. Fatal pneumonitis from congenital echovirus type 6 infection. Pediatr Infect Dis J 1987; 6: 1138–9
Cheeseman SH, Hirsch MS, Keller EW, et al. Fatal neonatal pneumonia caused by echovirus type 9. Am J Dis Child 1977; 131: 1169
Abzug MJ. The prognosis for neonates with enterovirus hepatitis and coagulopathy. Pediatr Infect Dis J 2001 Aug; 20: 758–63
Wang J, Atchison RW, Walpusk J, et al. Echovirus hepatic failure in infancy: report of four cases with speculation on the pathogenesis. Pediatr Dev Pathol 2001; 4: 454–60
Abzug MJ, Johnson SM. Catastrophic intracranial hemorrhage complicating perinatal viral infections. Pediatr Infect Dis J 2000; 19: 556–9
Ventura KC, Hawkins H, Smith MB, et al. Fatal neonatal echovirus 6 infection: autopsy case report and review of the literature. Mod Pathol 2001; 14: 85–90
Barre V, Marret S, Mendel I, et al. Enterovirus-associated haemophagocytic syndrome in a neonate. Acta Paediatr 1998; 87: 469–71
Tarcan A, Ozbek N, Gurakan B. Bone marrow failure with concurrent enteroviral infection in a newborn. Pediatr Infect Dis 2001 Jul; 20: 719–21
Spector SA, Straube RC. Protean manifestations of perinatal enterovirus infections. West J Med 1983; 138: 847–51
Hoi-shan Chan S, Lun KS. Ventricular aneurysm complicating neonatal coxsackie B4 myocarditis. Pediatr Cardiol 2001; 22: 247–9
Konen O, Rathaus V, Bauer S, et al. Progressive liver calcifications in neonatal coxsackievirus infection. Pediatr Radiol 2000; 30: 343–5
Farmer K, MacArthur BA, Clay MM. A follow-up study of 15 cases of neonatal meningoencephalitis due to coxsackie virus B5. J Pediatr 1975; 87: 568–71
Sells CJ, Carpenter RL, Ray CG. Sequelae of central-nervous-system enterovirus infections. N Engl J Med 1975; 293: 1–4
Wilfert CM, Thompson RJ, Sunder TR, et al. Longitudinal assessment of children with enteroviral meningitis during the first three months of life. Pediatrics 1981; 67: 811–5
Bergman I, Painter MJ, Wald ER, et al. Outcome in children with enteroviral meningitis during the first year of life. J Pediatr 1987; 110: 705–9
Rantakallio P, Saukkonen AL, Krause U. Follow-up study of 17 cases of neonatal coxsackie B5 meningitis and one with suspected myocarditis. Scand J Infect Dis 1970; 2: 25–8
Rorabaugh ML, Berlin LE, Rosenberg L, et al. Absence of neurodevelopmental sequelae from aseptic meningitis [abstract]. Pediatr Res 1992; 31: 177A
Brown GC, Karunas RS. Relationship of congenital anomalies and maternal infection with selected enteroviruses. Am J Epidemiol 1971; 95: 207–17
Cherry JD, Soriano F, Jahn CL. Search for perinatal viral infection: a prospective, clinical, virologic, and serologic study. Am J Dis Child 1968; 116: 245–50
Dagan R, Hall CB, Powell KR, et al. Epidemiology and laboratory diagnosis of infection with viral and bacterial pathogens in infants hospitalized for suspected sepsis. J Pediatr 1989; 115: 351–6
Rosenlew M, Stenvik M, Roivainen M, et al. A population-based prospective survey of newborn infants with suspected systemic infection: occurrence of sporadic enterovirus and adenovirus infections. J Clin Virol 1999; 12: 211–9
Shattuck KE, Chonmaitree T. The changing spectrum of neonatal meningitis over a fifteen-year period. Clin Pediatr 1992; 31: 130–6
Byington CL, Taggart EW, Carroll KC, et al. A polymerase chain reaction-based epidemiologic investigation of the incidence of nonpolio enteroviral infections in febrile and afebrile infants 90 days and younger. Pediatrics 1999; 103: E27
Rotbart HA, McCracken GH, Whitley RJ, et al. Clinical significance of enteroviruses in serious summer febrile illnesses of children. Pediatr Infect Dis J 1999; 18: 869–74
Horn P. Poliomyelitis in pregnancy: a twenty-year report from Los Angeles County, California. J Am Acad Obstet Gynecol 1955; 6: 121–37
Jones MJ, Kolb M, Votava HJ, et al. Intrauterine echovirus type 11 infection. Mayo Clin Proc 1980; 55: 509–12
Amstey MS, Miller RK, Menegus MA, et al. Enterovirus in pregnant women and the perfused placenta. Am J Obstet Gynecol 1988; 158: 775–82
Reyes MP, Ostrea EM, Roskamp J, et al. Disseminated neonatal echovirus 11 disease following antenatal maternal infection with a virus-positive cervix and virus-negative gastrointestinal tract. J Med Virol 1983; 12: 155–9
Reyes MP, Zalenski D, Smith F, et al. Coxsackievirus-positive cervices in women with febrile illnesses during the third trimester in pregnancy. Am J Obstet Gynecol 1986; 155: 159–61
Burch GE, Sun SC, Chu KC, et al. Interstitial and coxsackievirus B myocarditis in infants and children. JAMA 1968; 203: 1–8
Strong BS, Young SA. Intrauterine coxsackievirus, group B type 1, infection: viral cultivation from amniotic fluid in the third trimester. Am J Perinatol 1995; 55: 509–12
Philip AGS, Larson EJ. Overwhelming neonatal infection with ECHO 19 virus. J Pediatr 1973; 82: 391–7
Berkovich S, Smithwick EM. Transplacental infection due to ECHO virus type 22. J Pediatr 1968; 72: 94–6
Garcia AGP, Basso NGDS, Fonseca MEF, et al. Congenital echo virus infection: morphological and virological study of fetal and placental tissue. J Pathol 1990; 160: 123–7
Skeels MR, Williams JJ, Ricker FM. Perinatal echovirus infection [letter]. N Engl J Med 1981; 305: 1529
Batcup G, Holt P, Hambling MH, et al. Placental and fetal pathology in coxsackie virus A9 infection: a case report. Histopathology 1985; 9: 1227–35
Garcia AGP, Basso NGDS, Fonseca MEF, et al. Enterovirus associated placental morphology: a light, virological, electron microscopic and immunohistologic study. Placenta 1991; 12: 533–47
Nielsen JL, Berryman GK, Hankins GDV. Intrauterine fetal death and the isolation of echovirus 27 from amniotic fluid. J Infect Dis 1988; 158: 501–2
Brightman VJ, McNair Scott TF, Westphal M, et al. An outbreak of coxsackie B-5 virus infection in a newborn nursery. J Pediatr 1966; 69: 179–92
Kinney JS, McCray E, Kaplan JE, et al. Risk factors associated with echovirus 11 infection in a hospital nursery. Pediatr Infect Dis J 1986; 5: 192–7
Nagington J, Wreghitt TG, Gandy G, et al. Fatal echovirus 11 infections in outbreak in special-care baby unit. Lancet 1978; II: 725–8
Rabkin CS, Telzak EE, Ho MS, et al. Outbreak of echovirus 11 infection in hospitalized neonates. Pediatr Infect Dis J 1988; 7: 186–90
Jankovic B, Pasic S, Kanjuh B, et al. Severe neonatal echovirus 17 infection during a nursery outbreak. Pediatr Infect Dis J 1999; 18: 393–4
Pasic S, Jankovic B, Abinun M, et al. Intravenous immunoglobulin prophylaxis in an echovirus 6 and echovirus 4 nursery outbreak. Pediatr Infect Dis J 1997; 16: 718–20
Modlin JF, Polk BF, Horton P, et al. Perinatal echovirus infection: risk of transmission during a community outbreak. N Engl J Med 1981; 305: 368–71
Lonnrot M, Knip M, Roivainen M, et al. Onset of type 1 diabetes mellitus in infancy after enterovirus infections. Diabet Med 1998; 15: 431–4
Abzug MJ, Keyserling HL, Lee ML, et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995; 20: 1201–6
Sawada T, Kohno Y, Ikegami H, et al. Detection of coxsackie B2 virus myocarditis in a neonate using T1-201 and I-123 BMIPP myocardial imaging. Clin Nucl Med 2000 Jan; 25: 77–8
Dagan R, Jenista JA, Prather SL, et al. Viremia in hospitalized children with enterovirus infections. J Pediatr 1985; 106: 397–401
Dahlquist GG, Boman JE, Juto P. Enteroviral RNA and IgM antibodies in early pregnancy and risk for childhood-onset IDDM in offspring. Diabetes Care 1999; 22: 364–5
Terletskaia-Ladwig E, Metzger C, Schalasta G, et al. Evaluation of enterovirus serological tests IgM-EIA and complement fixation in patients with meningitis, confirmed by detection of enteroviral RNA by RT-PCR in cerebrospinal fluid. J Med Virol 2000; 61: 221–7
Terletskaia-Ladwig E, Metzger C, Schalasta G, et al. A new enzyme immunoassay for the detection of enteroviruses in faecal specimens. J Med Virol 2000; 60: 439–45
Bourlet T, Gharbi J, Omar S, et al. Comparison of a rapid culture method combining an immunoperoxidase test and a group specific anti-VP1 monoclonal antibody with conventional virus isolation techniques for routine detection of enteroviruses in stools. J Med Virol 1998; 54: 204–9
Rotbart HA. Diagnosis of enteroviral meningitis with the polymerase chain reaction. J Pediatr 1990; 117: 85–9
Sawyer MH, Holland D, Aintablian N, et al. Diagnosis of enteroviral central nervous system infection by polymerase chain reaction during a large community outbreak. Pediatr Infect Dis J 1994; 13: 177–82
Rotbart HA, Ahmed A, Hickey S, et al. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. Pediatr Infect Dis J 1997; 16: 409–11
Ahmed A, Brito F, Goto C, et al. Clinical utility of the polymerase chain reaction for diagnosis of enteroviral meningitis in infancy. J Pediatr 1997; 131: 393–7
Schlessinger Y, Sawyer MH, Storch GA. Enteroviral meningitis in infancy: potential role for polymerase chain reaction in patient management. Pediatrics 1994; 94: 157–62
Rice SK, Heinl RE, Thornton LL, et al. Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis. Clin Infect Dis 1995; 20: 931–7
Romero JR, Hinrich SH, Cavalieri SJ, et al. Potential health care cost savings from PCR-based rapid diagnosis of enteroviral meningitis [abstract]. Pediatr Res 1996; 39: 139A
Abzug MJ, Loeffelholz M, Rotbart HA. Diagnosis of neonatal enterovirus infection by polymerase chain reaction. J Pediatr 1995; 26: 447–50
Yoshio H, Yamada M, Yokoi Y, et al. Diagnosis of neonatal enterovirus meningitis by reverse transcription-polymerase chain reaction. Kansenshogaku Zasshi 1997; 71: 1046–50
Chambon M, Delage C, Bailly JL, et al. Fatal hepatic necrosis in a neonate with echovirus 20 infection: use of the polymerase chain reaction to detect enterovirus in liver tissue. Clin Infect Dis 1997; 24: 523–4
Austin BJ, Croxson MC, Powell KF, et al. The successful containment of coxsackie B4 infection in a neonatal unit. J Paediatr Child Health 1999; 35: 102–4
Chambon M, Bailly JL, Beguet A, et al. An outbreak due to echovirus type 30 in a neonatal unit in France in 1997: usefulness of PCR diagnosis. J Hosp Infect 1999; 43: 63–8
Takami T, Kawashima H, Takei Y, et al. Usefulness of nested PCR and sequence analysis in a nosocomial outbreak of neonatal enterovirus infection. J Clin Virol 1998; 11: 67–75
Bailly J, Beguet A, Chambon M, et al. Nosocomial transmission of echovirus 30: molecular evidence by phylogenetic analysis of the VP1 encoding sequence. J Clin Microbiol 2000; 38: 2889–92
Takami T, Sonodat S, Houjyo H, et al. Diagnosis of horizontal enterovirus infections in neonates by nested PCR and direct sequence analysis. J Hosp Infect 2000; 45: 283–7
Syriopoulou VP, Hadjichristodoulou CH, Daikos GL, et al. Clinical and epidemiological aspects of an enterovirus outbreak in a neonatal unit. J Hosp Infect 2002; 51: 275–80
Isacsohn M, Eidelman AI, Kaplan M, et al. Neonatal coxsackievirus group B infections: experience of a single department of neonatology. Isr J Med Sci 1994; 30: 371–4
Clavell M, Barkemeyer B, Martinez B, et al. Severe hepatitis in a newborn with coxsackievirus B5 infection. Clin Pediatr 1999; 38: 739–41
Chuang E, Maller ES, Hoffman MA, et al. Successful treatment of fulminant echovirus 11 infection in a neonate by orthotopic liver transplantation. J Pediatr Gastroenterol Nutr 1993; 17: 211–4
Van Saene HKF, Stoutenbeek CP, Faber-Nijholt R, et al. Selective decontamination of the digestive tract contributes to the control of disseminated intravascular coagulation in severe liver impairment. J Pediatr Gastroenterol Nutr 1986; 5: 476–80
Gilliam GL, Stokes KB, McLellan J, et al. Fulminant hepatic failure with intractable ascites due to an echovirus 11 infection successfully managed with a peritoneo-venous (LeVeen) shunt. J Pediatr Gastroenterol Nutr 1986; 5: 476–80
Nagington J. Echovirus 11 infection and prophylactic antiserum [letter]. Lancet 1982; II: 446
Dagan R, Prather S, Powell K, et al. Neutralizing antibodies to non-polio enteroviruses in human immune serum globulin. Pediatr Infect Dis J 1983; 2: 454–6
Hammond GW, Lukes H, Wells B, et al. Maternal and neonatal neutralizing antibody titers to selected enteroviruses. Pediatr Infect Dis J 1985; 4: 32–5
Wong SN, Tam AYC, Ng TH, et al. Fatal coxsackie B1 virus infection in neonates. Pediatr Infect Dis J 1989; 8: 638–41
Black S. Treatment of overwhelming neonatal ECHO 5 virus infection with intravenous gamma globulin [abstract no. 314]. In: American Society for Microbiology: program and abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1983: 140
Johnston JM, Overall JC. Intravenous immunoglobulin in disseminated neonatal echovirus 11 infection. Pediatr Infect Dis J 1989; 8: 254–6
Valduss D, Murray DL, Kama P. Use of intravenous immunoglobulin in twin neonates with disseminated coxsackie B1 infection. Clin Pediatr 1993; 32: 561–3
Kimura H, Minakami H, Harigaya A, et al. Treatment of neonatal infection caused by coxsackievirus B3. J Perinatal 1999; 19: 388–90
Jantausch BA, Luban NL, Duffy L, et al. Maternal plasma transfusion in the treatment of disseminated neonatal echovirus 11 infection. Pediatr Infect Dis J 1995; 14: 154–5
Rotbart HA. Antiviral therapy for enteroviral infections. Pediatr Infect Dis J 1999; 18: 632–3
Sawyer MH. Enterovirus infections: diagnosis and treatment. Pediatr Infect Dis J 1999 Dec; 18: 1033–40
Groarke JM, Pevear DC. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J Infect Dis 1999; 179: 1538–41
Pevear DC, Tull TM, Seipel ME. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999; 43: 2109–15
Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 2000; 181: 20–6
Shafran SD, Halota W, Gilbert D, et al. Pleconaril is effective for enteroviral meningitis in adolescents and adults: a randomized placebo-controlled multi-center trial [abstract no. 1904]. In: American Society for Microbiology: programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1999: 436
Beer K, ViroPharma Inc. ViroPharma announces results of viral respiratory infection and viral meningitis studies [online]. Available from URL: http://www.viropharma.com/index.htm [Accessed 2002 Dec 31]
Sawyer MH, Saez-Llorenz X, Aviles CL, et al. Oral pleconaril reduces the duration and severity of enterovirus meningitis in children [abstract no. 1012]. Pediatr Res 1999 Apr; 45(4): 173A
Beer K, ViroPharma Inc. ViroPharma Incorporated announces successful viral respiratory infection program with pleconaril [online]. Available from URL: http://www.viropharma.com/index.htm [Accessed 2002 Dec 31]
Beer K, ViroPharma Inc. Picovir™ (pleconaril) is first antiviral drug candidate shown in pivotal studies to treat the cause and symptoms of viral respiratory infection [online]. Available from URL: http://www.viropharma.com/index.htm [Accessed 2002 Dec 31]
Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 2001; 32: 228–35
Abzug MJ, Cloud G, Bradley J, et al. Double-blind, placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J 2003 Apr; 22: 335–40
Kearns GL, Bradley JS, Jacobs RJ, et al. Single dose pharmacokinetics of pleconaril in neonates. Pediatr Infect Dis J 2000; 19: 833–9
Bauer S, Gottesman G, Sirota L, et al. Severe coxsackie virus B infection in preterm newborns treated with pleconaril. Eur J Pediatr 2002; 161: 491–3
Aradottir E, Alonso EM, Shulman ST. Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr Infect Dis 2001 Apr; 20: 457–9
Beer K, ViroPharma Inc. ViroPharma provides further update on Picovir™ NDA [online]. Available from URL: http://www.viropharma.com/index.htm [Accessed 2002 Dec 31]
Wilson CW, Stevenson DK, Arvin AM. A concurrent epidemic of respiratory syncytial virus and echovirus 7 infections in an intensive care nursery. Pediatr Infect Dis J 1989; 8: 24–9
Carolane DJ, Long AM, McKeever PA, et al. Prevention of spread of echovirus 6 in a special care baby unit. Arch Dis Child 1985; 60: 674–6
Nagington J, Walker J, Gandy G. Use of normal immunoglobulin in an echovirus 11 outbreak in a special-care baby unit. Lancet 1983; II: 443–6
Acknowledgements
No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abzug, M.J. Presentation, Diagnosis, and Management of Enterovirus Infections in Neonates. Pediatr-Drugs 6, 1–10 (2004). https://doi.org/10.2165/00148581-200406010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00148581-200406010-00001